Study on Combined Vaccination With Quadrivalent Influenza Vaccine and 23-valent Pneumococcal Polysaccharide Vaccine
Influenza and Pneumonia
About this trial
This is an interventional prevention trial for Influenza and Pneumonia
Eligibility Criteria
Inclusion Criteria:
- The elderly aged 60 and above;
- The subjects and/or guardians can understand and voluntarily sign the informed consent form;
- Proven legal identity.
Exclusion Criteria:
- Received any circulating seasonal influenza vaccine prior to enrollment;
- Have received any pneumococcal vaccine within 5 years;
- History of severe allergic reactions to vaccines (such as acute anaphylaxis, angioneurotic edema, dyspnea, etc.);
- History of uncontrolled epilepsy and other serious neurological disorders (e.g.transverse myelitis, Guillain-Barre syndrome, demyelinating disease, etc.)
- Fever,acute onset of chronic disease,severe uncontrolled chronic disease or acute disease at the time of vaccination;
- Receipt of other investigational drugs in the past 30 days;
- Receipt of attenuated live vaccines in the past 14 days;
- Receipt of inactivated or subunit vaccines in the past 7 days;
- According to the investigator's judgment, the subject has any other factors that are not suitable for participating in the clinical trial.
Sites / Locations
- Jingjiang Center for Diseases Control and Prevention
- Taizhou City Hospital of Traditional Chinese and Western Medicine
- Gaogang District Center for Disease Control and Prevention
- Xinghua Center for Disease Control and Prevention
Arms of the Study
Arm 1
Arm 2
Arm 3
Experimental
Experimental
Experimental
Combined immunization group
Non combined immunization group
Safety group
160 subjects received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.
There were two subgroups in non combined immunization group,and 160 subjects in each subgroup.The non combined immunization subgroup 1 received one dose of quadrivalent influenza vaccine on day 0 and one dose of 23-valent pneumococcal polysaccharide vaccine on day 28.The non combined immunization subgroup 2 received one dose of 23-valent pneumococcal polysaccharide vaccine on day 0 and one dose of quadrivalent influenza vaccine on day 28.
2520 subjects were enrolled and received one dose of quadrivalent influenza vaccine and one dose of 23-valent pneumococcal polysaccharide vaccine on day 0.